Literature DB >> 17238014

(11)C-acetate PET imaging in prostate cancer.

Michael J Morris, Howard I Scher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17238014     DOI： 10.1007/s00259-006-0281-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  16 in total

1.  Clinical states in prostate cancer: toward a dynamic model of disease progression.

Authors:  H I Scher; G Heller
Journal:  Urology       Date:  2000-03       Impact factor: 2.649

2.  11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Authors:  Nobuyuki Oyama; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Keith C Fischer; Jeff M Michalski; Adam S Kibel; Gerald L Andriole; Joel Picus; Michael J Welch
Journal:  J Nucl Med       Date:  2003-04       Impact factor: 10.057

3.  Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium.

Authors:  J J Armbrecht; D B Buxton; H R Schelbert
Journal:  Circulation       Date:  1990-05       Impact factor: 29.690

4.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Authors:  G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

Review 5.  Prostate specific antigen only progression of prostate cancer.

Authors:  J W Moul
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

6.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

7.  Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.

Authors:  E Fricke; S Machtens; M Hofmann; J van den Hoff; S Bergh; T Brunkhorst; G J Meyer; J H Karstens; W H Knapp; A R Boerner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-13       Impact factor: 9.236

8.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma.

Authors:  J Kotzerke; J Prang; B Neumaier; B Volkmer; A Guhlmann; K Kleinschmidt; R Hautmann; S N Reske
Journal:  Eur J Nucl Med       Date:  2000-09

9.  Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.

Authors:  Matthew S Katz; Michael J Zelefsky; Ennapadam S Venkatraman; Zvi Fuks; Amanda Hummer; Steven A Leibel
Journal:  J Clin Oncol       Date:  2003-02-01       Impact factor: 44.544

10.  Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer.

Authors:  Jörg Kotzerke; Björn G Volkmer; Bernd Neumaier; Jürgen E Gschwend; Richard E Hautmann; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-27       Impact factor: 9.236
View more
  16 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Malignant lipogenesis defined by 11C-acetate PET/CT predicts prostate cancer-specific survival in patients with biochemical relapse after prostatectomy.

Authors:  Naresh Regula; Michael Häggman; Silvia Johansson; Jens Sörensen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-08       Impact factor: 9.236

Review 4.  Beyond haematuria in uro oncology: imaging biomarkers lag behind needs.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01       Impact factor: 9.236

Review 5.  Application of metabolic PET imaging in radiation oncology.

Authors:  Aizhi Zhu; David M Marcus; Hui-Kuo G Shu; Hyunsuk Shim
Journal:  Radiat Res       Date:  2012-02-17       Impact factor: 2.841

Review 6.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

7.  11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction.

Authors:  Mohammed Haseebuddin; Farrokh Dehdashti; Barry A Siegel; Jingxia Liu; Elizabeth B Roth; Kenneth G Nepple; Cary L Siegel; Keith C Fischer; Adam S Kibel; Gerald L Andriole; Tom R Miller
Journal:  J Nucl Med       Date:  2013-03-07       Impact factor: 10.057

Review 8.  New agents and techniques for imaging prostate cancer.

Authors:  Atif Zaheer; Steve Y Cho; Martin G Pomper
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

9.  Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.

Authors:  E Pelosi; V Arena; A Skanjeti; V Pirro; A Douroukas; A Pupi; M Mancini
Journal:  Radiol Med       Date:  2008-04-14       Impact factor: 3.469

Review 10.  Non-invasive molecular imaging of prostate cancer lymph node metastasis.

Authors:  Frédéric Pouliot; Mai Johnson; Lily Wu
Journal:  Trends Mol Med       Date:  2009-05-29       Impact factor: 11.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.